Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer

After the successful development of targeted therapy and immunotherapy for the treat-ment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treat-ment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted ther-apies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunother-apy in the adjuvant treatment of early-stage NSCLC.